Overview
Lobbying Costs
450,000€
Financial year: Jan 2016 - Dec 2016
Lobbyists (Full time equivalent)
1 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
SANOFI GENZYME (Genzyme)
EU Transparency Register
2946627525-90 First registered on 17 Oct 2008
Goals / Remit
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Main EU files targeted
rare disease policies, pharmaceutical dossiers and use of biotechnology in health care
in particular in the context of and related to:
- REGULATION (EC) No 141/2000 of 16 December 1999 on orphan medicinal products
- COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe's challenges - Brussels, 11.11.2008 COM(2008) 679 final
- EU Net HTA Joint action
- RD Action Joint Action
- IMIAddress
Head Office
Kendall Street, 500
Cambridge MA 02142
UNITED STATESEU Office
rue de la science 14
Brussels 1040
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 50% 1 25% 2 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Ms Vinciane Pirard (Sr Director Public Affairs)
Person with legal responsibility
Mr David Meeker (Executive Vice President and Head of Sanofi Genzyme)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2016 - Dec 2016
Lobbying costs for closed financial year
450,000€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
Expert Group on Rare diseases
ACC
None
Groups (European Parliament)
None
Communication activities
None
Other activities
To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.
Meetings
Meetings
None declared